Abcam completes $340m strategic acquisition and expands kit capacity and capability

- completing $340m strategic acquisition of biovision - expanding facilities in eugene, further growing kits and assays portfolio - supporting the growing demand of the sector and accelerating execution of strategic plan cambridge, england, oct. 27, 2021 /prnewswire/ -- abcam (aim:abc; nasdaq:abcm), a global innovator in life sciences reagents and tools, today announces the successful completion of its acquisition of biovision and the expansion of its immunoassay capacity in eugene, or. across the life sciences sector, the events of the last 18 months have amplified the need for efficient workflows and robust data generation, to enable the faster delivery of positive outcomes for science and health.
ABCM Ratings Summary
ABCM Quant Ranking